Haloperidol-associated stealth liposomes: A potent carrier for delivering genes to human breast cancer cells

Amarnath Mukherjee, Tekkatte Krishnamurthy Prasad, Nalam Madhusudhana Rao, Rajkumar Banerjee

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Sigma receptors are membrane-bound proteins that are overexpressed in certain human malignancies including breast cancer. These receptors show very high affinity for various sigma ligands including neuroleptics like haloperidol. We hypothesized that in associating haloperidol-linked lipid into the cationic lipid-DNA complex, we can specifically target and deliver genes to breast cancer cells that overexpress sigma receptors. In the present study, haloperidol was chemically modified to conjugate at the distal end of the polyethylene glycol-linked phospholipid, which was then incorporated into the cationic liposome known to condense and deliver genes inside cells. The resulting haloperidol-conjugated targeted lipoplex showed at least 10-fold higher (p < 0.001) reporter gene expression in MCF-7 cells than control lipoplex. The reporter gene expression of the targeted lipoplex was significantly blocked by haloperidol (p < 0.001) and by another sigma ligand, 1,3-ditolylguanidine (p < 0.001) in the majority of cationic lipid to DNA charge ratios (±). Spironolactone-mediated sigma receptor down-regulation enabled MCF-7 to show 10-fold lower transgene expression with targeted lipoplex compared with that obtained in spironolactone-untreated cells. The targeted lipoplex generated nonspecific gene expression in sigma receptor-nonexpressing human cancer cells such as Hela, KB, HepG2, and Chinese hamster ovary cells. Moreover, the transgene expression remained unabated in physiologically relevant serum concentrations. This is the first study to demonstrate that haloperidol-targeted gene delivery systems can mediate efficient targeting of genes to sigma receptor-overexpressing breast cancer cells, thereby becoming a novel class of therapeutics for the treatment of human cancers.

Original languageEnglish (US)
Pages (from-to)15619-15627
Number of pages9
JournalJournal of Biological Chemistry
Volume280
Issue number16
DOIs
StatePublished - Apr 22 2005
Externally publishedYes

Fingerprint

sigma Receptors
Haloperidol
Liposomes
Genes
Cells
Breast Neoplasms
Gene expression
Spironolactone
Transgenes
Lipids
Reporter Genes
Gene Expression
Ligands
Gene Transfer Techniques
Neoplasms
Gene Targeting
DNA
MCF-7 Cells
Cricetulus
Antipsychotic Agents

ASJC Scopus subject areas

  • Biochemistry

Cite this

Haloperidol-associated stealth liposomes : A potent carrier for delivering genes to human breast cancer cells. / Mukherjee, Amarnath; Prasad, Tekkatte Krishnamurthy; Rao, Nalam Madhusudhana; Banerjee, Rajkumar.

In: Journal of Biological Chemistry, Vol. 280, No. 16, 22.04.2005, p. 15619-15627.

Research output: Contribution to journalArticle

Mukherjee, Amarnath ; Prasad, Tekkatte Krishnamurthy ; Rao, Nalam Madhusudhana ; Banerjee, Rajkumar. / Haloperidol-associated stealth liposomes : A potent carrier for delivering genes to human breast cancer cells. In: Journal of Biological Chemistry. 2005 ; Vol. 280, No. 16. pp. 15619-15627.
@article{1048370a81f6423f8978fa4c84c9d236,
title = "Haloperidol-associated stealth liposomes: A potent carrier for delivering genes to human breast cancer cells",
abstract = "Sigma receptors are membrane-bound proteins that are overexpressed in certain human malignancies including breast cancer. These receptors show very high affinity for various sigma ligands including neuroleptics like haloperidol. We hypothesized that in associating haloperidol-linked lipid into the cationic lipid-DNA complex, we can specifically target and deliver genes to breast cancer cells that overexpress sigma receptors. In the present study, haloperidol was chemically modified to conjugate at the distal end of the polyethylene glycol-linked phospholipid, which was then incorporated into the cationic liposome known to condense and deliver genes inside cells. The resulting haloperidol-conjugated targeted lipoplex showed at least 10-fold higher (p < 0.001) reporter gene expression in MCF-7 cells than control lipoplex. The reporter gene expression of the targeted lipoplex was significantly blocked by haloperidol (p < 0.001) and by another sigma ligand, 1,3-ditolylguanidine (p < 0.001) in the majority of cationic lipid to DNA charge ratios (±). Spironolactone-mediated sigma receptor down-regulation enabled MCF-7 to show 10-fold lower transgene expression with targeted lipoplex compared with that obtained in spironolactone-untreated cells. The targeted lipoplex generated nonspecific gene expression in sigma receptor-nonexpressing human cancer cells such as Hela, KB, HepG2, and Chinese hamster ovary cells. Moreover, the transgene expression remained unabated in physiologically relevant serum concentrations. This is the first study to demonstrate that haloperidol-targeted gene delivery systems can mediate efficient targeting of genes to sigma receptor-overexpressing breast cancer cells, thereby becoming a novel class of therapeutics for the treatment of human cancers.",
author = "Amarnath Mukherjee and Prasad, {Tekkatte Krishnamurthy} and Rao, {Nalam Madhusudhana} and Rajkumar Banerjee",
year = "2005",
month = "4",
day = "22",
doi = "10.1074/jbc.M409723200",
language = "English (US)",
volume = "280",
pages = "15619--15627",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "16",

}

TY - JOUR

T1 - Haloperidol-associated stealth liposomes

T2 - A potent carrier for delivering genes to human breast cancer cells

AU - Mukherjee, Amarnath

AU - Prasad, Tekkatte Krishnamurthy

AU - Rao, Nalam Madhusudhana

AU - Banerjee, Rajkumar

PY - 2005/4/22

Y1 - 2005/4/22

N2 - Sigma receptors are membrane-bound proteins that are overexpressed in certain human malignancies including breast cancer. These receptors show very high affinity for various sigma ligands including neuroleptics like haloperidol. We hypothesized that in associating haloperidol-linked lipid into the cationic lipid-DNA complex, we can specifically target and deliver genes to breast cancer cells that overexpress sigma receptors. In the present study, haloperidol was chemically modified to conjugate at the distal end of the polyethylene glycol-linked phospholipid, which was then incorporated into the cationic liposome known to condense and deliver genes inside cells. The resulting haloperidol-conjugated targeted lipoplex showed at least 10-fold higher (p < 0.001) reporter gene expression in MCF-7 cells than control lipoplex. The reporter gene expression of the targeted lipoplex was significantly blocked by haloperidol (p < 0.001) and by another sigma ligand, 1,3-ditolylguanidine (p < 0.001) in the majority of cationic lipid to DNA charge ratios (±). Spironolactone-mediated sigma receptor down-regulation enabled MCF-7 to show 10-fold lower transgene expression with targeted lipoplex compared with that obtained in spironolactone-untreated cells. The targeted lipoplex generated nonspecific gene expression in sigma receptor-nonexpressing human cancer cells such as Hela, KB, HepG2, and Chinese hamster ovary cells. Moreover, the transgene expression remained unabated in physiologically relevant serum concentrations. This is the first study to demonstrate that haloperidol-targeted gene delivery systems can mediate efficient targeting of genes to sigma receptor-overexpressing breast cancer cells, thereby becoming a novel class of therapeutics for the treatment of human cancers.

AB - Sigma receptors are membrane-bound proteins that are overexpressed in certain human malignancies including breast cancer. These receptors show very high affinity for various sigma ligands including neuroleptics like haloperidol. We hypothesized that in associating haloperidol-linked lipid into the cationic lipid-DNA complex, we can specifically target and deliver genes to breast cancer cells that overexpress sigma receptors. In the present study, haloperidol was chemically modified to conjugate at the distal end of the polyethylene glycol-linked phospholipid, which was then incorporated into the cationic liposome known to condense and deliver genes inside cells. The resulting haloperidol-conjugated targeted lipoplex showed at least 10-fold higher (p < 0.001) reporter gene expression in MCF-7 cells than control lipoplex. The reporter gene expression of the targeted lipoplex was significantly blocked by haloperidol (p < 0.001) and by another sigma ligand, 1,3-ditolylguanidine (p < 0.001) in the majority of cationic lipid to DNA charge ratios (±). Spironolactone-mediated sigma receptor down-regulation enabled MCF-7 to show 10-fold lower transgene expression with targeted lipoplex compared with that obtained in spironolactone-untreated cells. The targeted lipoplex generated nonspecific gene expression in sigma receptor-nonexpressing human cancer cells such as Hela, KB, HepG2, and Chinese hamster ovary cells. Moreover, the transgene expression remained unabated in physiologically relevant serum concentrations. This is the first study to demonstrate that haloperidol-targeted gene delivery systems can mediate efficient targeting of genes to sigma receptor-overexpressing breast cancer cells, thereby becoming a novel class of therapeutics for the treatment of human cancers.

UR - http://www.scopus.com/inward/record.url?scp=18144403764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18144403764&partnerID=8YFLogxK

U2 - 10.1074/jbc.M409723200

DO - 10.1074/jbc.M409723200

M3 - Article

C2 - 15695518

AN - SCOPUS:18144403764

VL - 280

SP - 15619

EP - 15627

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 16

ER -